Amifampridine Phosphate

DRUG7 trials

Conditions

AChR Myasthenia GravisCongenital Myasthenic SyndromeLambert Eaton Myasthenic SyndromeLambert-Eaton Myasthenic SyndromeMuscular Atrophy, SpinalMyasthenia Gravis, GeneralizedMyasthenia Gravis, MuSKMyasthenic Syndromes, Congenital

Phase 2

Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients

CompletedNCT03781479

Catalyst Pharmaceuticals, Inc.Muscular Atrophy, Spinal

Start: 2019-01-21End: 2020-07-23Updated: 2021-06-01

Phase 3

A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

CompletedNCT01377922

Catalyst Pharmaceuticals, Inc.Lambert Eaton Myasthenic Syndrome

Start: 2011-06-30End: 2016-07-31Updated: 2018-01-04

Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes

CompletedNCT02562066

Catalyst Pharmaceuticals, Inc.Myasthenic Syndromes, Congenital

Start: 2016-01-31End: 2019-10-31Updated: 2021-04-02

Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)

CompletedNCT02970162

Catalyst Pharmaceuticals, Inc.Lambert-Eaton Myasthenic Syndrome

Start: 2016-11-30End: 2017-10-31Updated: 2018-12-24

Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG

CompletedNCT03304054

Catalyst Pharmaceuticals, Inc.Myasthenia Gravis, Generalized

Start: 2018-04-18End: 2020-03-15Updated: 2024-03-12

Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

TerminatedNCT03579966

Catalyst Pharmaceuticals, Inc.AChR Myasthenia Gravis, Myasthenia Gravis, MuSK

Start: 2018-06-11End: 2022-08-05Updated: 2024-05-07

Unknown Phase

Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome

NCT02189720

Catalyst Pharmaceuticals, Inc.Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome, Nystagmus, Acquired

Updated: 2025-03-26

Related Papers

Amifampridine safety and efficacy in spinal muscular atrophy ambulatory patients: a randomized, placebo-controlled, crossover phase 2 trial.